This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.

This week, we will discuss the SLEEP-HD trial, which examined if trazodone or CBT are better than placebo in helping people sleep.

This week, we will discuss the recently published KDIGO lupus guidelines. Published a couple of years after the big GN guidelines - let us dive in to see what’s new in lupus nephritis

This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?

2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!

This week we will discuss the article from Lancet on the addition of an ASI to background RASi and empagliflozin. Did this work?

This week, the last 2023’ NephJC resurfaces an old dilemma, in a different SPACE- non-cardiac surgery. Should we STOP ACEi, or do we know better?

This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.

This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?

This week, we will have a salty debate on what nephrologists love the most: hyponatremia and numbers. The main question: are guideline hyponatremia rates a waste of time?

This week on NephJC we are hashing out the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial!

This week, we will discuss some groundbreaking work on elucidating the adaptive and maladaptive cellular transcription and gene activation of the kidney in healthy and diseased states.

Classic scenario: young doctor, old patient with asymptomatic hypertension…
This week we are going against our instinct to normalize blood pressure numbers and listening to our wise elders.

What do you do when you suspect AIN (and eosinophils aren’t helpful) and you can’t get a kidney biopsy? CXCL9 is a newly discovered urinary marker that may help in the diagnosis of AIN. This week we will discuss the process of isolating and utilizing this new diagnostic test.

Help keep NephJC a vital, original, and unbiased source of medical education.

This week, we put our best fluid forward to discuss whether balanced crystalloids reduce the incidence of DGF after deceased donor kidney transplant compared to normal saline.

In this edition of NephTrials, we will discuss the importance of PROS, PROMS, PREMS, anchoring the discussion to the SWIFT trial

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?

This week, we will discuss a systematic review challenging a common practice: the use of sodium thiosulfate in calciphylaxis.

This week, we will discuss the effects of oral bicarbonate therapy in kidney transplant recipients.
Preserve-Transplant Study from Lancet.

This week, we will discuss another IgA Nephropathy trial - Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.

This week, we will discuss the resounding triumph of rituximab in maintenance therapy for ANCA-associated vasculitis. RIP Azathioprine?

This week, we will discuss Inaxaplin for APOL1 mediated kidney disease (AMKD). Taking the octopus by the horns.

This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.

This week, we will discuss the MAIN trial of MMF monotherapy in IgA Nephropathy. Pairs nicely with the NephMadness IgA Region discussion!